ReproCyc ParvoFLEX


porcine parvovirosis vaccine (inactivated)

This medicine is authorised for use in the European Union.


ReproCyc ParvoFLEX is a veterinary vaccine given to female pigs to protect their unborn piglets from porcine parvovirus infection via the placenta. Porcine parvovirus causes infertility, still births and small litters in female pigs. ReproCyc ParvoFLEX contains inactivated (killed) porcine parvovirus strain 27a viral protein 2.

This EPAR was last updated on 30/04/2020

Authorisation details

Product details
ReproCyc ParvoFLEX
Agency product number
Active substance
Porcine parvovirus, strain 27a, viral protein 2
International non-proprietary name (INN) or common name
porcine parvovirosis vaccine (inactivated)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein

Product information

30/10/2019 ReproCyc ParvoFLEX - EMEA/V/C/004858 - IA/0002/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

For active immunisation of gilts and sows from the age of 5 months to protect progeny against transplacental infection caused by porcine parvovirus.

Assessment history

How useful was this page?

Add your rating